Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Neurology|October 10, 2023
Initiation and Duration of Breastfeeding in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs StudyElizabeth E Gerard, Kimford J Meador, Chelsea P Robalino, et al.
Drug and Alcohol Dependence|December 14, 2019
Prevalence and treatment of opioid use disorders among primary care patients in six health systemsGwen Lapham, Denise M Boudreau, Eric A Johnson, et al.
JAMA Neurology|June 7, 2021
Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs StudyKimford J Meador, Morris J Cohen, David W Loring, et al.
The Lancet. Neurology|July 21, 2023
Cognitive outcomes at age 3 years in children with fetal exposure to antiseizure medications (MONEAD study) in the USA: a prospective, observational cohort studyKimford J Meador, Morris J Cohen, David W Loring, et al.
JAMA Network Open|November 22, 2024
Nurse Care Management of Opioid Use Disorder Treatment After 3 Years: A Secondary Analysis of the PROUD Cluster Randomized Clinical TrialGwen T Lapham, Noorie Hyun, Jennifer F Bobb, et al.
JAMA Neurology|November 20, 2023
Behavioral Outcomes and Neurodevelopmental Disorders Among Children of Women With EpilepsyMorris J Cohen, Kimford J Meador, David W Loring, et al.
JAMA Internal Medicine|March 16, 2026
Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical TrialT John Winhusen, Michelle R Lofwall, Frankie Kropp, et al.
Neurology|May 29, 2024
Association of Prenatal Exposure to Antiseizure Medications With Creative and Executive Function at Age 4.5 YearsKimford J Meador, Morris J Cohen, David W Loring, et al.
BMC Health Services Research|December 29, 2022
Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: comparison of trial and non-trial clinics in the same health systemsPaige D Wartko, Hongxiang Qiu, Abisola E Idu, et al.
Lancet (London, England)|November 19, 2017
Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trialJoshua D Lee, Edward V Nunes, Patricia Novo, et al.
Pageof 7